SCHEMBL1600939

SCHEMBL1600939

CC(C)(C)[SiH2]OC(C)(C)c1cc(C(F)(F)F)ccc1[C@@H](O)C1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 4/20 0.48
PSMB11 A5LHX3 1/20 0.32
PSMA7 O14818 1/20 0.32
PSMB1 P20618 1/20 0.32
PSMA1 P25786 1/20 0.32
PSMA2 P25787 1/20 0.32
PSMA3 P25788 1/20 0.32
PSMA4 P25789 1/20 0.32
PSMB8 P28062 1/20 0.32
PSMB9 P28065 1/20 0.32
PSMA5 P28066 1/20 0.32
PSMB4 P28070 1/20 0.32
PSMB6 P28072 1/20 0.32
PSMB5 P28074 1/20 0.32
PSMB10 P40306 1/20 0.32
PSMB3 P49720 1/20 0.32
PSMB2 P49721 1/20 0.32
PSMA6 P60900 1/20 0.32
PSMA8 Q8TAA3 1/20 0.32
PSMB7 Q99436 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27740294 1.00 PDE2A (0.48) PDE2APSMB11PSMA7PSMB1PSMA1
SCHEMBL1601510 0.75 CES2 (0.39) CYP2C19PTGDR2EPHX2CES2MEN1
SCHEMBL22619655 0.74 PDE2A (0.71) PDE2APSMB11PSMA7PSMB1PSMA1
SCHEMBL1601403 0.69 PDE2A (0.46) PDE2APSMB11PSMA7PSMB1PSMA1
SCHEMBL1600937 0.69 PDE2A (0.46) PDE2APSMB11PSMA7PSMB1PSMA1
SCHEMBL1600845 0.67 PDE2A (0.47) PDE2APSMB11PSMA7PSMB1PSMA1
SCHEMBL1350819 0.66 PDE2A (1.00) PDE2AMEN1KMT2ACYP3A4
SCHEMBL26081058 0.66 DHODH (0.50) PDE2ACES2MEN1LMNAHTT
SCHEMBL1350263 0.65 PDE2A (0.69) PDE2ACYP1A2CYP2D6CYP2C19LMNA
SCHEMBL13905314 0.64 PDE2A (0.41) PDE2AEPHX1PTGDR2EPHX2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7919506-B2 Dibenzyl amine compounds and derivatives PFIZER INC. (US) 2011-04-05 US disclosed
WO-2009027785-A2 1, 3-OXAZOLE DERIVATIVES AS CETP INHIBITORS PFIZER PRODUCTS INC. (US) 2009-03-05 WO disclosed
EP-1996564-A1 DIBENZYL AMINE COMPOUNDS AND DERIVATIVES Pfizer Products Incorporated (US) 2008-12-03 EP disclosed
WO-2007105050-A1 DIBENZYL AMINE COMPOUNDS AND DERIVATIVES PFIZER PRODUCTS INC. (US) 2007-09-20 WO disclosed
US-20070213371-A1 Dibenzyl Amine Compounds and Derivatives PFIZER INC 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213371-A1 Dibenzyl Amine Compounds and Derivatives APOB, LDLR, CETP PDE2A 404/4885PSMB11 4135/4885PSMA7 4059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.